Effectiveness and Safety of Baricitinib in Patients With Moderate-to-Severe Refractory Alopecia Areata in Real World: An Open-Label, Single-Center Study

    December 2023 in “ Journal of Cosmetic Dermatology ”
    Lingbo Bi, Chaofan Wang, Yimei Du … Weiyuan Sun
    Studysummary This study found that baricitinib, taken for 24 weeks, significantly reduced alopecia severity in patients with moderate-to-severe alopecia areata, with 50% showing marked improvement and overall favorable safety and efficacy reported.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 17

    1. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata JAMA Dermatology · 2023
    2. Treatment of Moderate-to-Severe Alopecia Areata in Pre-Adolescent Children with Baricitinib British Journal of Dermatology · 2023
    3. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials American Journal of Clinical Dermatology · 2023
    4. Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-Analysis Acta dermato-venereologica · 2023
    5. Real-World Experience and Long-Term Evaluation of Tofacitinib in Refractory Alopecia Areata: A Prospective, Open-Label, Single-Center Study in Asian Arab Population Dermatologic Therapy · 2022
    6. Efficacy and Safety of Baricitinib in Patients With Refractory Alopecia Areata Dermatologic Therapy · 2022
    7. Two Phase 3 Trials of Baricitinib for Alopecia Areata The New England Journal of Medicine · 2022
    8. Clinical Efficacy of Adipocyte-Derived Stem Cells Conditioned Media Combined with Micro-Injury in Refractory Patch of Alopecia Areata Archives of Dermatological Research · 2021
    9. Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review Dermatology and Therapy · 2021
    10. The Alopecia Areata Investigator Global Assessment Scale: A Measure for Evaluating Clinically Meaningful Success in Clinical Trials British Journal of Dermatology · 2020
    11. Alopecia Areata: A Multifactorial Autoimmune Condition Journal of autoimmunity · 2018
    12. JAK-Inhibitors in Dermatology: Current Evidence and Future Applications Journal of dermatological treatment · 2018
    13. Alopecia Areata: Treatment Options and Efficacy Journal of the American Academy of Dermatology · 2017
    14. Alopecia Areata: Overview and Insights from January 2018 Journal of The American Academy of Dermatology · 2017
    15. Objective Outcome Measures: Collecting Meaningful Data on Alopecia Areata Journal of The American Academy of Dermatology · 2017
    16. SALT II: A New Take on the Severity of Alopecia Tool for Determining Percentage Scalp Hair Loss Journal of The American Academy of Dermatology · 2016
    17. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014

    Related research 1

    1. Serum Zinc Concentration in Patients With Alopecia Areata Acta dermato-venereologica (Print) · 2023